| Genomic imprinting in development, growth, behavior and stem cells RN Plasschaert, MS Bartolomei Development 141 (9), 1805-1813, 2014 | 257 | 2014 |
| A role for CTCF and cohesin in subtelomere chromatin organization, TERRA transcription, and telomere end protection Z Deng, Z Wang, N Stong, R Plasschaert, A Moczan, HS Chen, S Hu, ... The EMBO journal 31 (21), 4165-4178, 2012 | 194 | 2012 |
| Tissue-specific regulation and function of Grb10 during growth and neuronal commitment RN Plasschaert, MS Bartolomei Proceedings of the National Academy of Sciences 112 (22), 6841-6847, 2015 | 68 | 2015 |
| CTCF binding site sequence differences are associated with unique regulatory and functional trends during embryonic stem cell differentiation RN Plasschaert, S Vigneau, I Tempera, R Gupta, J Maksimoska, L Everett, ... Nucleic acids research 42 (2), 774-789, 2013 | 68 | 2013 |
| CTCF binding to the first intron of the major immediate early (MIE) gene of human cytomegalovirus (HCMV) negatively regulates MIE gene expression and HCMV replication FP Martínez, R Cruz, F Lu, R Plasschaert, Z Deng, YA Rivera-Molina, ... Journal of virology 88 (13), 7389-7401, 2014 | 59 | 2014 |
| High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing RN Plasschaert, MP DeAndrade, F Hull, Q Nguyen, T Peterson, A Yan, ... Molecular Therapy 30 (10), 3209-3225, 2022 | 8 | 2022 |
| A long genetic explanation RN Plasschaert, MS Bartolomei Nature 501 (7465), 36-37, 2013 | 7 | 2013 |
| Compositions and methods for treating neurocognitive disorders C Mason, O Cooper, M Deandrade, R Plasschaert, NPN VAN TIL US Patent App. 17/427,298, 2022 | 1 | 2022 |
| Genetically engineered microglia-like cells have therapeutic potential for neurodegenerative disease RN Plasschaert, MP DeAndrade, F Hull, Q Nguyen, T Peterson, A Yan, ... bioRxiv, 2021.09. 16.460703, 2021 | 1 | 2021 |
| Preclinical lentiviral vector-mediated hematopoietic stem and progenitor cell gene therapy corrects Pompe disease-related muscle and neurological manifestations JK Yoon, JW Schindler, M Loperfido, C Baricordi, MP DeAndrade, ... bioRxiv, 2023.11. 03.565442, 2023 | | 2023 |
| Compositions and methods for treating neurocognitive disorders C Mason, O Cooper, R Plasschaert US Patent App. 18/014,311, 2023 | | 2023 |
| Compositions and methods for treating neurocognitive disorders C Mason, O Cooper, M Deandrade, R Plasschaert, NP Van Til US Patent App. 17/427,429, 2022 | | 2022 |
| Compositions and methods for treating neurocognitive disorders C Mason, O Cooper, M Deandrade, R Plasschaert, NPN VAN TIL US Patent App. 17/427,252, 2022 | | 2022 |
| Transplantation of gene-modified haematopoietic stem cells and their application in murine models of neurodegenerative disease RN Plasschaert, MP DeAndrade, F Hull, Q Nguyen, T Peterson, ... HUMAN GENE THERAPY 32 (19-20), A49-A49, 2021 | | 2021 |
| A comprehensive characterization of biodistribution and single-cell states of HSC-derived microglia upon ex-vivo lentiviral gene therapy in murine models of neurological disease RN Plasschaert, M DeAndrade, M Loperfido, C Baricordi, L Barbarossa, ... 2021 Alzheimer's Association International Conference, 2021 | | 2021 |
| Understanding the Recruitment and Regulatory Functions of CTCF During Development RN Plasschaert University of Pennsylvania, 2015 | | 2015 |
Italo TemperaAssociate Professor, The Wistar InstituteVerified email at wistar.org
